News

Forthcoming in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, this paper describes the context of the problem of access to medicines in developing countries. The authors detail policies and proposals intended to increase access to both 'global' and 'neglected' diseases, including pricing, compulsory licensing, donations and 'push' and 'pull' mechanisms to stimulate R&D.

In forthcoming chapter in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, experts in the field outline the evolution of cost-effectiveness analysis (CEA) through its use as part of health technology assessment. The authors also explore the theoretical and practical issues that have arisen as the result of using CEA of drugs to make decisions about resource allocation, pricing and use and offer some important recommendations.

On 31 May, OHE will be moving its offices to Southside, 7th Floor, 105 Victoria Street, London SW1E 6QT. Telephone/fax numbers and e-mails will remain the same. We look forward to welcoming you to our new location.

Just released is an OHE Research Paper that examines whether and how decisions about allocating resources for health care differ across the NHS and, particularly, in comparison to decisions by NICE. If important differences exist, the efficiency of resources allocation may be affected negatively.

Released today is an OHE study commissioned by Cancer Research UK that explores the interdependence between publicly funded and charity funded medical research. In particular, the study focuses on whether and how changes in the levels of government funding affect private funding for charities and, more broadly, medical research and the UK economy as a whole.

Pages